A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(6 sites)

United States

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California

James J. Peters VA Medical Center, Bronx, NY, The Bronx, New York

VA Portland Health Care System, Portland, OR, Portland, Oregon

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina

South Texas Health Care System, San Antonio, TX, San Antonio, Texas

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington